glp 1 receptor agonists and dpp 4 inhibitors GLP-1 or DPP-4 inhibitors: How to guide the clinician? The effect of DPP-4 inhibitors,

Equillium retains rights to the candidate, which is in the Phase III EQUATOR trial (NCT05263999) in acute graft-versus-host disease (aGVHD)

They are often marketed as needle-free alternatives to prescription GLP-1 injections and may be described as Wegovy patches or Mounjaro patches

Researchers have also noted that 70% of diabetes patients discontinue GLP-1 receptor agonist treatment within two years, limiting the long-term efficacy of these drugs

Does insurance cover Mounjaro alternatives

Critics argue even low doses could increase infection susceptibility in vulnerable people

While DPP-4 expression is significantly increased in patients with obesity and T2DM, the incretin effect is markedly impaired